July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Retinal Ganglion cell Functional Recovery After IOP lowering treatment in Glaucoma Suspects
Author Affiliations & Notes
  • Peter H Derr
    Diopsys, New Jersey, United States
  • Andrew Tirsi
    MEETH, New York, United States
  • Benny Wong
    MEETH, New York, United States
  • Victoria Rohring
    MEETH, New York, United States
  • Jung Min Lee
    MEETH, New York, United States
  • lukas Schwartz
    MEETH, New York, United States
  • Alberto Gonzalez Garcia
    Diopsys, New Jersey, United States
  • Sung Chul Park
    MEETH, New York, United States
  • Celso Tello
    MEETH, New York, United States
  • Footnotes
    Commercial Relationships   Peter Derr, Diosys (E); Andrew Tirsi, None; Benny Wong, None; Victoria Rohring, None; Jung Min Lee, None; lukas Schwartz, None; Alberto Gonzalez Garcia, Diopsys (E); Sung Chul Park, None; Celso Tello, Diopsys (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2450. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter H Derr, Andrew Tirsi, Benny Wong, Victoria Rohring, Jung Min Lee, lukas Schwartz, Alberto Gonzalez Garcia, Sung Chul Park, Celso Tello; Retinal Ganglion cell Functional Recovery After IOP lowering treatment in Glaucoma Suspects. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2450. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the ability of the Pattern Electroretinogram (PERG) to detect retinal ganglion cell (RGC) function improvement in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analogue drops

Methods : Six GS subjects (8 eyes), necessitating IOP lowering treatment based on their clinical examination, were observed at MEETH over an average of 12 months, during which they were tested with Diopsys NOVA PERG (Diopsys©, Inc. Pine Brook, NJ), and other clinical tests, at baseline and 3 months after the treatment was started (on average of 3.1 ± 2.2 months). One-way repeated measures ANOVA [Mag, MagD and MagD/Mag ratio (R)] were conducted as appropriate. This study was IRB approved and informed consent was signed by each subject.

Results : One-way repeated measures ANOVA was conducted to determine whether there was a statistically significant difference in PERG parameters over the course of 3 months after treatment was started. There were no outliers and the data was normally distributed at each time point, as assessed by boxplot and Shapiro-Wilk test (p >0.05), respectively. The assumption of sphericity was met, as assessed by Mauchly’s test of sphericity. Over time, the treatment intervention did elicit statistically significant changes in magD (F (1, 7) = 10.076, p= 0.016, partial ω2 =0.590) and R (F (1, 7) = 10.455, p= 0.014, partial ω2 =0.599), with MagD and R increasing from pre-intervention (0.944± 0.44 and 0.71± 0.15) to 1.25± 0.36 and 0.82± 0.08, respectively. The intervention did elicit significant changes in IOP decreasing from 21.86± 2.1 to 16.86± 1.9 (22.8 % decrease)

Conclusions : After reducing IOP by 22.8% for a duration on average of 3 months, PERG detected an improved RGC function, mostly by increased latency. More longitudinal studies are needed to evaluate the beneficial effects of early IOP reductions in slowing progression, and to assess the ability of PERG in monitoring treatment efficacy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×